Neovascular age-related macular degeneration is a serious eye condition that affects millions of people worldwide, primarily those over 60 years of age. While this disease can cause rapid vision loss, modern treatments offer hope for preserving sight and maintaining quality of life.

What You Need to Know About Treatment Options

When someone receives a diagnosis of neovascular age-related macular degeneration, also known as wet AMD, the primary goal of treatment is to slow or stop the progression of vision loss. Unlike the dry form of macular degeneration, wet AMD develops when abnormal blood vessels grow beneath the macula, the central part of the retina responsible for sharp, straight-ahead vision. These fragile blood vessels leak blood and fluid, causing swelling and damage that can lead to permanent loss of central vision if left untreated.^[1]

Treatment approaches depend on several factors, including how quickly the disease was detected, the extent of blood vessel growth, and the individual characteristics of each patient. The good news is that wet AMD can be managed with therapies approved by medical societies and healthcare authorities worldwide. While current treatments cannot cure the disease or reverse vision loss that has already occurred, they can effectively control the abnormal blood vessel growth and preserve remaining vision.^[4]

Beyond standard approved treatments, medical research continues to explore new therapeutic options through clinical trials. These studies investigate innovative approaches that may offer longer-lasting effects, reduced treatment burden, or improved outcomes for patients who do not respond optimally to existing therapies. Understanding both current treatment options and emerging therapies can help patients and their families make informed decisions about managing this condition.^[1]

Standard Treatment Methods for Wet AMD

The treatment landscape for neovascular age-related macular degeneration was transformed with the discovery of vascular endothelial growth factor, commonly called VEGF. This is a family of proteins in the body that promotes the growth of abnormal new blood vessels in the eye, a process called neovascularization. When VEGF levels become too high, these abnormal vessels form, leak, and damage the macula, leading to the vision loss characteristic of wet AMD.^[4]

To combat this process, doctors use medications called anti-VEGF drugs, which block the action of VEGF and help control the growth of abnormal blood vessels. These medications are delivered directly into the eye through injections, a procedure called intravitreal injection. While this might sound intimidating, the procedure is performed with numbing eye drops that minimize discomfort, and the injections are typically quick and well-tolerated by most patients.^[7]

Currently, there are five anti-VEGF drugs approved for treating wet AMD. These include bevacizumab (Avastin), ranibizumab (Lucentis), aflibercept (Eylea), brolucizumab (Beovu), and faricimab (Vabysmo). Each of these medications works by blocking VEGF, but they differ slightly in their molecular structure, how long they remain active in the eye, and how often they need to be administered.^[4]

Treatment typically begins with an induction phase, where patients receive three initial monthly injections to quickly bring the abnormal blood vessel activity under control. After this initial period, doctors use one of several treatment schedules to maintain control of the disease. The most common approaches include “treat and extend,” where the time between injections is gradually increased as long as the disease remains controlled; “as needed” treatment, where injections are given only when signs of disease activity return; or continued monthly injections for patients who require more frequent treatment.^[11]

Some patients respond well and may eventually require injections only every 10 to 16 weeks, while others need more frequent treatment to keep the disease under control. The treatment schedule is highly individualized and determined through regular monitoring with specialized imaging tests that allow doctors to see fluid accumulation and blood vessel activity in the retina.^[4]

In addition to anti-VEGF injections, another treatment called photodynamic therapy, or PDT, is occasionally used. This treatment involves injecting a light-sensitive medicine called verteporfin into the arm, followed by shining a special type of laser onto the abnormal blood vessels in the eye. The laser activates the medicine, which then breaks down the problem blood vessels. However, photodynamic therapy is much less commonly used today than anti-VEGF injections and is typically reserved for specific situations where it might be helpful alongside injections.^[7]

Side effects from anti-VEGF injections are generally uncommon but can include temporary eye discomfort, redness, or increased eye pressure. Rarely, more serious complications such as infection or retinal detachment can occur. The risk of infection is minimized through careful cleaning of the eye before injection and the use of sterile techniques. Most patients experience preserved or even improved vision with ongoing treatment, making the benefits of therapy far outweigh the risks for most individuals.^[4]

Promising Therapies Being Tested in Clinical Trials

Despite the success of anti-VEGF therapy, researchers recognize that there is still unmet need in treating neovascular AMD. Many patients do not respond optimally to current treatments, some lose their response over time, and the frequent injection schedule can be burdensome for patients and healthcare systems. These limitations have driven extensive research into new and improved therapeutic approaches.^[9]

One important insight from recent research is that blocking VEGF-A alone, as most current agents do, may not be sufficient for all patients. Scientists have discovered that other proteins and biological pathways also contribute to abnormal blood vessel growth and fluid accumulation in wet AMD. This has led to the development of medications that target multiple pathways simultaneously, potentially offering better disease control and longer-lasting effects.^[9]

For example, faricimab (Vabysmo), one of the newer approved anti-VEGF medications, blocks not only VEGF but also another protein called angiopoietin-2. By targeting both of these growth factors, faricimab may provide more comprehensive control of blood vessel growth and leakage. Clinical trials have shown that this dual-targeting approach can allow some patients to extend the time between injections while maintaining good disease control.^[4]

Another exciting area of research involves gene therapy. Instead of requiring repeated injections of medication, gene therapy aims to deliver genetic instructions directly to cells in the eye, allowing them to produce their own anti-VEGF proteins continuously. This approach could potentially reduce or even eliminate the need for frequent injections. Several gene therapy candidates for wet AMD are currently being tested in clinical trials in various phases.^[1]

Clinical trials progress through distinct phases, each designed to answer specific questions about a new treatment. Phase I trials primarily assess safety and determine appropriate dosing in a small number of patients. Phase II trials expand to more patients and begin to evaluate how well the treatment works while continuing to monitor safety. Phase III trials involve large numbers of patients and compare the new treatment directly to standard treatments to determine if it offers advantages in effectiveness, safety, or convenience.^[9]

Researchers are also investigating Rho-kinase inhibitors, a class of drugs that work through a different mechanism than anti-VEGF agents. These medications may help reduce fibrosis and scarring in the macula, which can occur as a complication of wet AMD and lead to permanent vision loss even when the abnormal blood vessels are controlled. By addressing this different aspect of the disease, Rho-kinase inhibitors could potentially be used alongside anti-VEGF therapy to improve outcomes.^[1]

Interestingly, an older medication called levodopa, which has been used for decades to treat Parkinson’s disease, is being studied for its potential effects in macular degeneration. Early research suggests it may have protective effects on retinal cells, though more studies are needed to understand whether it offers meaningful benefits for AMD patients.^[1]

Some clinical trials are exploring longer-acting formulations of existing anti-VEGF drugs or new delivery systems that could extend the duration of effect. These innovations aim to reduce the treatment burden by allowing patients to receive injections less frequently while maintaining disease control. Such advances would significantly improve quality of life for patients who currently require monthly or bimonthly treatments.^[9]

Clinical trials for wet AMD are conducted at specialized eye care centers around the world, including locations in the United States, Europe, and other regions. Patient eligibility for trials depends on factors such as the stage and characteristics of their disease, previous treatments received, and overall health status. Individuals interested in participating in clinical trials should discuss this option with their eye care specialist, who can provide information about available studies and help determine if participation might be appropriate.^[9]

Most common treatment methods

• Anti-VEGF Injections
  • Intravitreal injections of medications that block vascular endothelial growth factor (VEGF)
  • Five approved drugs: bevacizumab (Avastin), ranibizumab (Lucentis), aflibercept (Eylea), brolucizumab (Beovu), and faricimab (Vabysmo)
  • Delivered directly into the eye after numbing with anesthetic drops
  • Typically started with three monthly injections during induction phase
  • Maintenance treatment may be monthly, as-needed, or treat-and-extend schedule depending on patient response
  • Some patients can extend to injections every 10-16 weeks with newer agents
  • Most common and effective treatment for preserving vision in wet AMD
• Photodynamic Therapy (PDT)
  • Uses light-sensitive medicine called verteporfin injected into the arm
  • Special “cold laser” activates the medicine to break down abnormal blood vessels
  • Less commonly used than anti-VEGF injections
  • Sometimes used in combination with anti-VEGF therapy in specific cases
  • Requires placing special contact lens on eye to guide the laser
  • May require multiple treatment sessions
• Gene Therapy (Experimental)
  • Delivers genetic instructions to eye cells to produce anti-VEGF proteins continuously
  • Aims to reduce or eliminate need for frequent injections
  • Currently being tested in clinical trials
  • Represents potential future alternative to repeated injections
• Multi-pathway Targeting Agents
  • Medications that block multiple growth factors simultaneously
  • Faricimab targets both VEGF and angiopoietin-2
  • May provide more comprehensive disease control
  • Can potentially extend time between injections for some patients
  • Other multi-targeted therapies under investigation in clinical trials
• Rho-kinase Inhibitors (Experimental)
  • Work through different mechanism than anti-VEGF drugs
  • May help reduce fibrosis and scarring in the macula
  • Could potentially be used alongside anti-VEGF therapy
  • Currently being studied in research trials

Monitoring and Ongoing Care

Successful management of neovascular AMD requires more than just receiving treatments—it also involves careful monitoring to detect changes in disease activity and adjust treatment accordingly. Patients typically undergo regular eye examinations that include specialized imaging tests to visualize the retina and detect signs of fluid accumulation or blood vessel activity.^[12]

Optical coherence tomography, or OCT, is a key imaging technology used to monitor wet AMD. This non-invasive test uses light waves to create detailed cross-sectional images of the retina, allowing doctors to see even small amounts of fluid or thickening in the macula. OCT scans are typically performed at each visit to help determine whether treatment is needed and how well the current therapy is working.^[4]

Visual acuity testing, which measures how well you can see at various distances, is another essential part of monitoring. Changes in visual acuity can indicate whether the disease is progressing or responding to treatment. Some clinical practice guidelines recommend using both OCT findings and visual acuity measurements together to make decisions about when to adjust anti-VEGF treatment intervals or change therapeutic approaches.^[12]

In addition to clinic-based monitoring, patients are often given an Amsler grid—a simple paper with a grid pattern—to check their vision at home daily. This tool can help detect early changes in central vision, such as straight lines appearing wavy or new blank spots developing. Patients should contact their eye doctor immediately if they notice such changes, as prompt treatment can help prevent further vision loss.^[6]

The frequency of monitoring visits varies depending on the treatment schedule. Patients on monthly injections typically have monthly appointments, while those on treat-and-extend schedules may have visits that gradually space out to every 8, 10, 12, or more weeks if the disease remains stable. Even patients with well-controlled disease should continue regular monitoring, as wet AMD can become active again at any time.^[11]

Living Well with Wet AMD

Receiving a diagnosis of neovascular age-related macular degeneration understandably causes worry and uncertainty. However, with modern treatments and supportive care, many people with wet AMD can maintain good vision and continue enjoying their daily activities. Adapting to any level of vision loss requires learning new strategies and sometimes using assistive devices, but most people find they can manage remarkably well.^[18]

It’s important to remember that wet AMD affects only central vision—the sharp, detailed vision needed for tasks like reading and recognizing faces. Peripheral vision, which allows you to see things off to the sides, remains intact. This means that people with wet AMD will not become completely blind, even if they lose significant central vision. Most individuals retain enough vision to maintain independence in their daily lives.^[6]

Making modifications to your home environment can significantly improve function and safety. Increasing lighting throughout the house, especially in areas where you perform detailed tasks like the kitchen and bathroom, can make a substantial difference. Using task lighting, such as adjustable lamps that focus light directly on what you’re working on, helps maximize your remaining vision. High-contrast colors—for example, using dark placemats under white dishes or marking stair edges with bright tape—make objects easier to distinguish.^[17]

Low vision rehabilitation services offer valuable support for people adapting to vision loss. Low vision specialists can recommend and provide training on assistive devices such as magnifiers, large-print materials, talking watches and appliances, and specialized computer software that enlarges text or reads it aloud. Many people are surprised to discover how much these tools can help them continue reading, managing medications, and performing other important daily tasks.^[16]

Technology offers increasingly sophisticated solutions for people with visual impairment. Smartphones and tablets have built-in accessibility features like voice commands, screen magnification, and text-to-speech functions that can be customized to individual needs. Electronic magnifiers and wearable devices can help with tasks ranging from reading restaurant menus to watching grandchildren’s sporting events.^[19]

Maintaining overall health is an important aspect of managing wet AMD. A balanced diet rich in leafy green vegetables, fish high in omega-3 fatty acids, and colorful fruits and vegetables supports eye health. Regular exercise, maintaining healthy blood pressure and cholesterol levels, and not smoking all contribute to slowing disease progression and protecting overall wellbeing. Some studies suggest that specific vitamin and mineral supplements may benefit people with AMD, though you should consult with your doctor before starting any supplements.^[13]

The emotional impact of vision loss should not be underestimated. Many people experience anxiety, frustration, or depression when dealing with wet AMD, and these feelings are completely normal. However, if low mood persists for more than two weeks or significantly interferes with daily life, it’s important to seek support from healthcare providers. Counseling, support groups where you can connect with others facing similar challenges, and sometimes medication can help address these emotional aspects of living with vision loss.^[16]

Support organizations specifically for people with macular disease offer valuable resources, including educational materials, peer support groups, and helplines staffed by trained professionals who can answer questions and provide guidance. Many of these organizations also advocate for improved access to treatments and support services. Connecting with others who understand the challenges of living with wet AMD can reduce feelings of isolation and provide practical tips for managing daily life.^[18]

For individuals whose vision loss affects their ability to drive, alternative transportation options should be explored. Family members, friends, community transportation services, and ride-sharing programs can help maintain independence and social connections. In some regions, legal requirements mandate reporting vision loss to driving authorities, so it’s important to understand and follow local regulations regarding driving with visual impairment.^[16]

Finally, staying engaged with activities you enjoy, maintaining social connections, and finding new hobbies adapted to your current vision level all contribute to quality of life. Many people find that they can continue most of their favorite activities with some modifications. The key is patience with yourself as you adapt, willingness to try new approaches, and acceptance of help when needed. Living well with wet AMD is not only possible—it’s something thousands of people accomplish every day.^[18]